Wednesday 12 March 2014 – GSK Vaccines, Wavre, Belgium
Programme
This workshop is sponsored by:
You can download this program from the pdf in attachment at the bottom of this page.
|
8:00-8:50 |
Coffee |
|
|
8:50-9:00 |
Welcome |
JM. Wilkin, GSK Vaccines, Belgium |
|
Morning session: Introductory lectures |
||
|
9:00-9:40 |
Nucleotide therapies: Past failures and future challenges |
L. Coney, Huntingdon Life Sciences, UK |
| 9:40-10:20 |
Safety evaluation of gene therapy products including inhaled products |
M.Mc Elroy Charles River Laboratories, UK |
| 10:20-10:45 |
Regulatory perspective on the safety assessment of oligonucleotides and gene therapies |
C. Beuneu Federal Agency for Medicines and Health Products, Belgium |
|
10:45-11:05 |
Coffee break |
|
| 11:05-11:35 |
The personalized medicine approach in orphan disease: development of oligonucleotides for the treatment of Duchenne's Muscular Distrophy |
C. den Besten Prosensa, The Netherlands |
|
11:35-12:05 |
Toxicologic pathology of anitsense oligonucleotides |
C. Sobry, CitoxLab, France |
| 12:05-12:45 |
Non-GLP pharmacology and the GLP toxicology studies to support the use of CpG as adjuvant in anti-nicotine and anti-IgE therapeutic vaccines |
M. McCluskie, Pfizer, Canada |
|
12:45-13:45 |
Lunch and networking |
|
|
Afternoon session: Case studies analysis |
||
|
13:45-14:00 |
Introduction to breakout sessions | |
| 14:00-15:00 | Breakout sessions |
|
|
15:00-15:20 |
Coffee break |
|
|
15:20-16:50 |
Case study reporting and discussion |
|
|
16:50-17:00 |
Concluding remarks |
M. Martens President BelTox |
|
Organizing Committee : Judith Baumeister (Ablynx, B), Michaela Damsten, Frédérique
Delannois, Camille Planty and Lawrence Segal (GSK Vaccines), Miek Desmidt, Ad Knaapen and Ilham Smyej (Johnson & Johnson, B), Annick Cauvin and Miranda Cornet (UCB Pharma, B) |
||